DOCSLIB.ORG

Customs Tariff - Schedule Xxi - 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Customs Tariff - Schedule Xxi - 1 CUSTOMS TARIFF - SCHEDULE XXI - 1 Section XXI WORKS OF ART, COLLECTORS' PIECES AND ANTIQUES Issued January 1, 2013 CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2013 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT: Free Artificial bait; Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels. 9903.00.00 Articles and materials that enter into the cost of manufacture or repair Free CCCT, LDCT, GPT, UST, of the following, and articles for use in the following: MT, MUST, CIAT, CT, Agricultural or horticultural elevators or conveyors; CRT, IT, NT, SLT, PT, Agricultural or horticultural machinery for soil preparation or COLT, JT, PAT: Free cultivation, including domestic rotary tillers and lawn or sports-ground rollers, and pneumatic tires and inner tubes for use therewith; Agricultural or horticultural machines for cleaning, sorting or grading seed, grain or dried leguminous vegetables; Agricultural or horticultural machines of heading 84.33, not including mowers for lawns, parks or sports-grounds, and pneumatic tires and inner tubes for use therewith; Agricultural or horticultural machines of heading 84.36; Agricultural or horticultural mechanical appliances (whether or not hand-operated) for projecting, dispersing or spraying liquids or powders, parts thereof and pneumatic tires and inner tubes for use therewith; Air heaters and parts thereof, for orchards; Apparatus for sterilizing bulbs; Apparatus for the destruction of predatory animals by the discharge of poisonous cartridges, and poisonous cartridges therefor; Automatic bale stacking wagons, grain carts and silage wagons, and parts thereof; Automatic explosive bird-scaring devices and twin-shot cartridges therefore; Binder or baler twine of polyethylene, polypropylene, sisal or other textile fibres of the genus Agave; Carbon dioxide generators and parts thereof, to be employed in controlling the atmosphere in greenhouses or in storage plants for fresh fruit or fresh vegetables; Centrifuges for testing butterfat, milk or cream; Clippers for animals and for use on the farm; Combination excavating and transporting scrapers for use on the farm, and pneumatic tires and inner tubes for use therewith; Revised April 1, 2013 Issued April 1, 2013 99 - 2 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9903.00.00 Combination machinery for bagging or boxing and weighing, or Continued machinery for filling, for use with fresh fruit or vegetables; Cream separators; Egg cooling cabinets and furniture therefor; Electrical bird-scaring devices which produce sounds simulating natural alarm cries of birds, not including recorders or reproducers using magnetic tape; Fanning mills; Farm or logging wagons or sleds; Forage boxes for self-loading or self-unloading trailers and semi- trailers for agricultural purposes; Front-end loader attachments or snow-blowers for tractors, for use on the farm; Fuel tanks, engines, generators, electric accumulators, switchboards and panels, and parts thereof, all for generating electricity for agricultural or horticultural purposes; Generating sets for use on the farm for farm purposes only; Grain or hay dryers; Grain roasters; Gravity discharge boxes for farm wagons; Header or swather transporters and parts thereof; Hitches and couplings for use on the farm; Hydraulic hoists for unloading vehicles, for use on the farm; Instruments, appliances and machines designed for measuring the moisture content of agricultural produce; Levellers for use on the farm and pneumatic tires and inner tubes for use therewith; Machinery for bunching or tying cut flowers, vegetables or nursery stock; Machinery for filling bottles, for use in the beverage industry; Machinery for packing fresh fruit or vegetables from the dumper, feed table, bin or hopper stage to the box or bag closing stage; Machinery for power filling, for use in the dairy industry; Milk coolers and furniture therefor; Milking machines; Plucking, scalding, washing, singeing or eviscerating machinery to be employed in the preparation of poultry; Post hole diggers; Pressure testing apparatus for determining the maturity of fruit; Pruning shears or hooks; Spraying lorries (spraying trucks) for spreading dry or liquid fertilizer or sludge for agricultural use, and pneumatic tires and inner tubes for use therewith; Sprinkle or trickle irrigation systems and parts thereof, for use on the farm or in greenhouses; Steel stanchions for confining livestock either in pens or individually; Traction ditching machines (not being ploughs) and buckets, shovels, grabs, grips, pneumatic tires and inner tubes for use therewith; Tractors powered by an internal combustion engine, not including tractors of the type used on railway station platforms, road tractors for semi-trailers or tractors of a kind for hauling logs (log skidders), and buckets, shovels, grabs, grips, bulldozer or angledozer blades, scarifiers, pneumatic tires and inner tubes for use therewith and for use on the farm; chassis fitted with engines therefor, cabs therefor, and parts and Issued April 1, 2013 99 - 3 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9903.00.00 accessories thereof, other than bumpers and bumper parts, safety seat Continued belts and suspension shock-absorbers; Windmills. 9904.00.00 Kosher goods of heading 22.04 or 22.05 that originate in Israel or N/A CIAT: Free another CIFTA beneficiary. 9905.00.00 The following Passover products for use during the Passover Free CCCT, LDCT, GPT, UST, holiday and so marked, imported during the period beginning two MT, MUST, CIAT, CT, months before the eve of the first day of that holiday and ending on CRT, PT, COLT, JT, the last day of the holiday: PAT: Free Cake mix, pancake mix and baked goods; Canned fish and fish products other than pickled herring; Canned fruits and vegetables; Chocolates, candy and gum (excluding fruit jelly candy and jelly rings, chocolate-covered jellies, chocolate-covered marshmallows, and chocolate-covered orange peels); Dried apples; Grapeseed oil; Jam; Jelly powders and puddings; Juices (except apple juice) and juice blends (not containing apple juice); Matzo and matzo products; Margarine of tariff item No. 1517.10.10, not exceeding 50,000 kg each Passover holiday; Olives; Potato chips; Salad dressings and ketchup; Soups (including borsch) and gravies; Tomato ketchup, paste, purée and sauce; Vegetable shortening; and Vinegar. Under this Act, the Governor in Council may amend the above list of products. 9906.00.00 Foodstuffs and other consumable goods, other than alcoholic Free CCCT, LDCT, GPT, UST, beverages and tobacco products, imported for exclusive use in carrying MT, MUST, CIAT, CT, out field studies by an expedition conducted or sponsored by a CRT, IT, NT, SLT, PT, scientific or cultural organization, an institution of learning or a foreign COLT, JT, PAT: Free government, the participants in which are non-residents of Canada and the conductees or sponsors of which have undertaken to make available to the Government of Canada all information obtained in Canada as a result of the expedition's field studies. 9908.00.00 Utility vehicles of heading 87.03 and lorries (trucks) or shuttle cars of Free CCCT, LDCT, GPT, UST, heading 87.04, for use underground in mining or in developing mineral MT, MUST, CIAT, CT, deposits; CRT, IT, NT, SLT, PT, Articles (excluding tires and inner tubes) for use in the foregoing COLT, JT, PAT: Free equipment, or for use in loading machinery for loading coal or for loading minerals directly from the working face of a mine, or for use in extracting machinery for extracting minerals directly from the working face of a mine. Revised April 1, 2013 Issued April 1, 2013 99 - 4 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9909.00.00 Well logging machinery or apparatus and seismic instruments, and parts Free CCCT, LDCT, GPT, UST, thereof, to be employed in the exploration, discovery, development, MT, MUST, CIAT, CT, maintenance, testing, depletion or production of oil or natural gas wells CRT, IT, NT, SLT, PT, or for use in drilling machinery to be employed in the exploration, COLT, JT, PAT: Free discovery, development or operation of potash or rock salt deposits, excluding the motor vehicle chassis portion and parts thereof of special purpose motor vehicles of heading 87.05, all other motor vehicles of Chapter 87 and geophysical instruments of heading 90.15.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Guaiana, G., Barbui, C., Caldwell, DM, Davies, SJC, Furukawa, TA
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Guaiana, G., Barbui, C., Caldwell, D. M., Davies, S. J. C., Furukawa, T. A., Imai, H., ... Cipriani, A. (2017). Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews, 2017(7), [CD012729]. https://doi.org/10.1002/14651858.CD012729 Publisher's PDF, also known as Version of record Link to published version (if available): 10.1002/14651858.CD012729 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Cochrane Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012729/full . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms Cochrane Database of Systematic Reviews Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis (Protocol) Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A Guaiana G, Barbui C, Caldwell DM, Davies SJC, Furukawa TA, Imai H, Koesters M, Tajika A, Bighelli I, Pompoli A, Cipriani A. Antidepressants, benzodiazepines and azapirones for panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2017, Issue 7.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • Neurobiological and Neurobehavioral Mechanisms of Chronic Alcohol Drinking
    Neurobiological and Neurobehavioral Mechanisms of Chronic Alcohol Drinking Neurobiological and Neurobehavioral Mechanisms of Chronic Alcohol Drinking Alcoholism comprises a set of complex behaviors seeking behaviors, have been developed. These in which an individual becomes increasingly models, which remain an integral part of the preoccupied with obtaining alcohol. These study of alcoholism, include animals that pref- behaviors ultimately lead to a loss of control over erentially drink solutions containing alcohol, consumption of the drug and to the development animals that self-administer alcohol during of tolerance, dependence, and impaired social and withdrawal, animals with a history of dependence occupational functioning. that self-administer alcohol, and animals that self- administer alcohol after a period of abstinence Although valuable information regarding toler- from the drug. Genetic models for alcoholism ance and dependence has been, and continues to also exist and include animals that have been bred be, gathered through human studies, much of the selectively for high alcohol consumption. Studies detailed understanding of the impact of exposure using such models are uncovering the systemic, to alcohol on behavior and on the biological cellular, and molecular neurobiological mech- mechanisms underlying those behaviors has been anisms that appear to contribute to chronic obtained through the use of animal models for alcohol consumption. The challenge of current alcoholism and a variety of in vitro, or cellular, and future studies is to understand which specific systems. Through the use of cellular systems and cellular and subcellular systems undergo mole- animal models, researchers can control the genetic cular changes to influence tolerance and depen- background and experimental conditions under dence in motivational systems that lead to which a specific alcohol-related behavior or chronic drinking.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Subject Index
    Subject Index A-64662 497 classification 11-14 AA-861 511 (fig) function 111-114 acebutolol 69,70 hemodynamic effects 110-121 brand names 868 (table) in hypertensive disease 114 dosage 83 (table), 860 (table) mechanism of action 110-121 intrinsic sympathomimetic activity 82 metabolism 108-110 pharmacological profile 83 (table) pharmacodynamics 110-121 see also diuretics 83 pharmacokinetics 108-110 acetazolamide 22, 24 sUbtypes 111,241-246 chemical structure 23 (fig), 24 (table) a2- 246 duration of action 39 (table) classification at central cardiovascular fractional sodium excretion 30 (table) sites 242-244 metabolism 37 definition at peripheral sites onset of action 39 (table) 241-242 peak of action 39 (table) a-adrenoceptor agonists 113 (table) pKa 37 (table) a-adrenoceptor antagonists 15, 105-125 plasma elimination half-life 37 antihypertensive activity 114-119 protein binding 37 (table) chemistry 106-108 renal site/mechanism of action 26, 30 combination with other drugs 123 (table) contraindications 123-124 site of action 29 differential antagonism 242 teratogenesis 800,800-802 dosage 121-123 tubular fluid/plasma-sodium drug interactions 123 concentrations ratio 30 (fig) effects on: c10nidine 240-241 see also diuretics guanfacine 240-241 acetylcholine 316 a-methyldopa 240-241 acetylsalicylic acid 53 hemodynamic profile 119-120 Actinomycetales extracts/compounds side effects 124 728 therapeutic use 121-123 adenosine-3, 5-cyclic monophosphate toxicity 124 (cAMP) 73 ~-adrenoceptor antagonists 66-67, 815 adenosine triphosphate 73,268 a-adrenoceptor
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub
    US 20200187851A1TE INI (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No .: US 2020/0187851 A1 Offenbacher et al. (43 ) Pub . Date : Jun . 18 , 2020 ( 54 ) PERIODONTAL DISEASE STRATIFICATION (52 ) U.S. CI. AND USES THEREOF CPC A61B 5/4552 (2013.01 ) ; G16H 20/10 ( 71) Applicant: The University of North Carolina at ( 2018.01) ; A61B 5/7275 ( 2013.01) ; A61B Chapel Hill , Chapel Hill , NC (US ) 5/7264 ( 2013.01 ) ( 72 ) Inventors: Steven Offenbacher, Chapel Hill , NC (US ) ; Thiago Morelli , Durham , NC ( 57 ) ABSTRACT (US ) ; Kevin Lee Moss, Graham , NC ( US ) ; James Douglas Beck , Chapel Described herein are methods of classifying periodontal Hill , NC (US ) patients and individual teeth . For example , disclosed is a method of diagnosing periodontal disease and / or risk of ( 21) Appl. No .: 16 /713,874 tooth loss in a subject that involves classifying teeth into one of 7 classes of periodontal disease. The method can include ( 22 ) Filed : Dec. 13 , 2019 the step of performing a dental examination on a patient and Related U.S. Application Data determining a periodontal profile class ( PPC ) . The method can further include the step of determining for each tooth a ( 60 ) Provisional application No.62 / 780,675 , filed on Dec. Tooth Profile Class ( TPC ) . The PPC and TPC can be used 17 , 2018 together to generate a composite risk score for an individual, which is referred to herein as the Index of Periodontal Risk Publication Classification ( IPR ) . In some embodiments , each stage of the disclosed (51 ) Int. Cl. PPC system is characterized by unique single nucleotide A61B 5/00 ( 2006.01 ) polymorphisms (SNPs ) associated with unique pathways , G16H 20/10 ( 2006.01 ) identifying unique druggable targets for each stage .
    [Show full text]
  • Cytoplasmic Localization of RXR Determines Outcome in Breast
    cancers Article Cytoplasmic Localization of RXRα Determines Outcome in Breast Cancer Alaleh Zati zehni 1,†, Falk Batz 1,†, Vincent Cavaillès 2 , Sophie Sixou 3,4, Till Kaltofen 1 , Simon Keckstein 1, Helene Hildegard Heidegger 1, Nina Ditsch 5, Sven Mahner 1, Udo Jeschke 1,5,* and Theresa Vilsmaier 1 1 Department of Obstetrics and Gynecology, University Hospital Munich LMU, 81377 Munich, Germany; [email protected] (A.Z.z.); [email protected] (F.B.); [email protected] (T.K.); [email protected] (S.K.); [email protected] (H.H.H.); [email protected] (S.M.); [email protected] (T.V.) 2 IRCM—Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université Montpellier, Parc Euromédecine, 208 rue des Apothicaires, CEDEX 5, F-34298 Montpellier, France; [email protected] 3 Faculté des Sciences Pharmaceutiques, Université Paul Sabatier Toulouse III, CEDEX 09, 31062 Toulouse, France; [email protected] 4 Cholesterol Metabolism and Therapeutic Innovations, Cancer Research Center of Toulouse (CRCT), UMR 1037, Université de Toulouse, CNRS, Inserm, UPS, 31037 Toulouse, France 5 Department of Obstetrics and Gynecology, University Hospital, 86156 Augsburg, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-8214-0016-5505 † These authors equally contributed to this work. Citation: Zati zehni, A.; Batz, F.; Cavaillès, V.; Sixou, S.; Kaltofen, T.; Simple Summary: Considering the immense development of today’s therapeutic approaches in on- Keckstein, S.; Heidegger, H.H.; Ditsch, cology towards customized therapy, this study aimed to assess the prognostic value of nuclear versus N.; Mahner, S.; Jeschke, U.; et al.
    [Show full text]
  • Attenuated 5-Hydroxytryptamine Receptor-Mediated Responses in Aortae from Streptozotocin-Induced Diabetic Rats G.M
    Br. J. Pharmacol. (1994), 111, 370-376 '." Macmillan Press Ltd, 1994 Attenuated 5-hydroxytryptamine receptor-mediated responses in aortae from streptozotocin-induced diabetic rats G.M. James, 1W.C. Hodgson, E.A. Davis & 2J.M. Haynes Department of Pharmacology, Monash University, Clayton, Victoria, Australia, 3168 1 This study was designed to examine further the attenuated contractile responses to 5-hydroxy- tryptamine (5-HT) previously observed in aortae from diabetic rats. 2 Cumulative concentration-response curves to 5-HT, and the 5-HT receptor agonists, at-methyl 5-HT (a-Me-5-HT, 5-HT21lc agonist), (± )-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI, 5-HT21IC agonist) and 5-carboxamidotryptamine (5-CT, 5-HTIA/1B/1D agonist), were examined in endothelium- intact and -denuded aortae from 2-week streptozotocin (STZ)-diabetic and control rats. 3 In endothelium-intact and -denuded aortae from diabetic rats, maximum responses to 5-HT and a-Me-5-HT were significantly reduced compared to those of aortae from control rats. Responses to these agonists were inhibited by the 5-HT21lc receptor antagonist, ketanserin (0.1 jAM). 4 The attenuated responses to 5-HT of aortae from diabetic rats were normalized by chronic insulin treatment of the rats (5 units day-', s.c.), but not by altering the glucose concentration of the bathing fluid. 5 The nitric oxide synthase inhibitor N-nitro-L-arginine (NOLA, 0.1 mM) significantly potentiated responses to both 5-HT and a-Me-5-HT in endothelium-intact aortae. However, the difference between maximum responses of aortae from diabetic and control rats was still evident in the presence of NOLA.
    [Show full text]